SpringWorks Therapeutics Inc - in H2 2024, Plans to File Marketing Authorization Application With EMA for Mirdametinib
SpringWorks Therapeutics公司計劃於2024年下半年向EMA提交Mirdametinib的營銷授權申請。
SpringWorks Therapeutics Inc - in H2 2024, Plans to File Marketing Authorization Application With EMA for Mirdametinib
SpringWorks Therapeutics公司計劃於2024年下半年向EMA提交Mirdametinib的營銷授權申請。
譯文內容由第三人軟體翻譯。